Stocktoria

Cellectar Biosciences, Inc. CLRB

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2005-05-20 · LEI

Cellectar Biosciences, Inc. statistics & valuation

Market cap$20.1M
P / B2.4×
Return on capital-224.7%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
2016201720182019202020212022202320242025
Return on equity (%)
-45.60% -126.10% -99.80% -155.60% -27.50% -73.00% -350.80% -311.90% -255.20% 2016201720182019202020212022202320242025
Shares outstanding
10.4M 1.7M 4.7M 9.4M 45.4M 6.1M 9.4M 20.7M 1.5M 4.2M 2016201720182019202020212022202320242025
Net debt ($)
2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-40.30% -105.40% -87.90% -115.00% -25.70% -64.80% -132.50% -354.20% -175.00% -145.50% 2016201720182019202020212022202320242025
Free cash flow margin (%)
2016201720182019202020212022202320242025
Debt / equity (×)
2016201720182019202020212022202320242025
EPS ($)
-$1.84 -$4.35 -$4.05 -$3.50 -$41.89 -$8.35 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Return on assets-145.5%-175.0%-354.2%-132.5%-64.8%-25.7%-115.0%-87.9%-105.4%-40.3%
Return on equity-255.2%-311.9%282.1%-350.8%-73.0%-27.5%-155.6%-99.8%-126.1%-45.6%
Current ratio2.962.580.413.719.1616.264.118.604.957.47

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.